Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGAV | P06756 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22201000 | 0.82 | ALDH1A1 (0.59) | POLBNAMPTALDH1A1 | |
| SCHEMBL4866294 | 0.81 | EPHX2 (0.97) | EPHX2KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL5639509 | 0.80 | EPHX2 (0.71) | EPHX2POLBKMT2ANPC1RAB9A | |
| SCHEMBL3822162 | 0.80 | EPHX2 (1.00) | EPHX2KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL7453800 | 0.79 | EPHX1 (0.70) | EPHX2POLBNAMPTALDH1A1L3MBTL1 | |
| SCHEMBL5142691 | 0.79 | ALDH1A1 (0.73) | EPHX2POLBKMT2ANPC1RAB9A | |
| SCHEMBL26154069 | 0.78 | EPHX2 (0.90) | EPHX2KMT2ANPC1RAB9ATDP1 | |
| SCHEMBL19444720 | 0.77 | NOTUM (0.57) | POLBKMT2ATDP1NAMPTMEN1 | |
| SCHEMBL31734582 | 0.77 | NAMPT (0.56) | EPHX2KMT2ANPC1RAB9AITGB3 | |
| SCHEMBL26949358 | 0.77 | NAMPT (0.56) | EPHX2KMT2ANPC1RAB9AITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773075-B2 | Modulators of p97 AAA ATPase activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773075-B2 | Modulators of p97 AAA ATPase activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220089565-A1 | MODULATORS OF P97 AAA ATPASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-03-24 | — | — | US | disclosed |
| US-11214560-B2 | Modulators of P97 AAA ATPase activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200216410-A1 | MODULATORS OF P97 AAA ATPASE ACTIVITY | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089565-A1 | MODULATORS OF P97 AAA ATPASE ACTIVITY | PSMG3, CDC37, AHSA1 | EPHX2 3623/4885POLB 686/4885KMT2A 2875/4885 |
| US-20200216410-A1 | MODULATORS OF P97 AAA ATPASE ACTIVITY | PSMG3, AHSA1, CDC37 | EPHX2 3670/4885POLB 747/4885KMT2A 2851/4885 |
| US-11214560-B2 | Modulators of P97 AAA ATPase activity | PSMG3, AHSA1, CDC37 | EPHX2 3670/4885POLB 747/4885KMT2A 2851/4885 |
| US-11773075-B2 | Modulators of p97 AAA ATPase activity | PSMG3, CDC37, AHSA1 | EPHX2 3623/4885POLB 686/4885KMT2A 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.